¼¼°èÀÇ ºñ¾ËÄڿüº Áö¹æ°£¿° ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀº 2024³â¿¡ 15¾ï ´Þ·¯·Î Æò°¡µÇ¾úÀ¸¸ç CAGR 25.8%·Î ¼ºÀåÇÏ¿© 2034³â¿¡´Â 148¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
NASH ¹ÙÀÌ¿À¸¶Ä¿´Â ºñ¾ËÄڿüº Áö¹æ °£ Áúȯ(NAFLD)¿¡¼ ÁøÈÇÏ´Â ½É°¢ÇÑ °£ ÁúȯÀÎ NASHÀÇ Á¸Àç¿Í ÁøÇàÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â »ý¹°ÇÐÀû ÁöÇ¥ÀÔ´Ï´Ù. ÀÇ·á Á¦°øÀÚµéÀº Á¶±â ¹ß°ß°ú Àû±ØÀûÀÎ °³ÀÔÀ» Á¡Á¡ ¿ì¼±½ÃÇϰí ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ¹ÙÀÌ¿À¸¶Ä¿ ¼ö¿ä´Â »ó´çÈ÷ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. Àû±ØÀûÀÎ °£Áúȯ ½ºÅ©¸®´×ÀÇ ÃßÁøÀº À§ÇèÇÑ Áý´ÜÀ» ´ë»óÀ¸·Î ÇÑ ÀÓ»óÀû ±Ç°íÀÇ ÁøÈ¿¡ ÀÇÇØ ´õ¿í °ÈµÇ°í ÀÖ½À´Ï´Ù. ¿©±â¿¡´Â NASH¸¦ ¹ßº´Çϱ⠽¬¿î ºñ¸¸À̳ª 2Çü ´ç´¢º´°ú °°Àº ´ë»ç ÀÌ»óÀÌ ÀÖ´Â »ç¶÷ÀÌ Æ÷ÇԵ˴ϴÙ.
°£ °ü·Ã ÇÕº´Áõ¿¡ ´ëÇÑ ÀνÄÀÌ Áõ°¡ÇÔ¿¡ µû¶ó °Ç° °ü¸® ½Ã½ºÅÛÀº ȯÀÚ °á°ú¸¦ °³¼±Çϱâ À§ÇØ ¹ÙÀÌ¿À ¸¶Ä¿ ±â¹Ý Áø´Ü Àü·«À» ÅëÇÕÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â Áúº´ÀÇ ÁøÇàÀ» ¸ð´ÏÅ͸µÇϰí, Ä¡·á È¿°ú¸¦ Æò°¡Çϰí, »õ·Î¿î Ä¡·á¹ýÀÇ ÇýÅÃÀ» ¹Þ±â ½¬¿î ȯÀÚ¸¦ È®ÀÎÇÒ ¼ö ÀÖ´Â °¡´É¼ºÀ» Á¦°øÇÕ´Ï´Ù. ¸ÂÃãÇü ÀÇ·á¿¡¼ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ¿ªÇÒÀº °£ÁúȯÀÇ Áø´Ü¡¤°ü¸® ¹æ¹ý¿¡ Å« º¯È¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. ³·Àº ħ½ÀÀû ¹æ¹ýÀÌ ¼±È£µÇ°í ÀÓ»ó ¿¬±¸¿¡¼ Á¤¹Ð Áø´ÜÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Çö´ë °Ç° °ü¸®¿¡¼ NASH ¹ÙÀÌ¿À ¸¶Ä¿ÀÇ Á߿伺ÀÌ ´õ¿í Ä¿Áö°í ÀÖ½À´Ï´Ù.
½ÃÀå ¹üÀ§ | |
---|---|
½ÃÀÛ ¿¬µµ | 2024³â |
¿¹Ãø ¿¬µµ | 2025-2034³â |
½ÃÀÛ ±Ý¾× | 15¾ï ´Þ·¯ |
¿¹Ãø ±Ý¾× | 148¾ï ´Þ·¯ |
CAGR | 25.8% |
½ÃÀåÀº ¹ÙÀÌ¿À ¸¶Ä¿À¯Çüº°·Î »êÈ ½ºÆ®·¹½º ¹ÙÀÌ¿À ¸¶Ä¿, °£ ¼¶À¯Áõ ¹ÙÀÌ¿À ¸¶Ä¿, Ç÷û ¹ÙÀÌ¿À ¸¶Ä¿, ¾ÆÆüÅä½Ã½º ¹ÙÀÌ¿À ¸¶Ä¿ µîÀ¸·Î ±¸ºÐµË´Ï´Ù. µ¡ºÙ¿© Ç÷û ¹ÙÀÌ¿À¸¶Ä¿°¡ 2024³â¿¡ 32.8%¸¦ Â÷ÁöÇß°í, ¸ÅÃâ¿¡¼ ÃÖ´ëÀÇ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ ºÎ¹®ÀÇ ¿ìÀ§¼ºÀº ÁÖ·Î, Ç÷¾× »ùÇøµÀÇ °£Æí¼º, ºñħ½ÀÀûÀÎ ¼ø¼, Áø´Ü, ¸ð´ÏÅ͸µ, ¿¹ÈÄ¿¡ ÀÚÁÖ »ç¿ëµÇ´Â °ÍÀÔ´Ï´Ù. Ç÷û ±â¹Ý ¹ÙÀÌ¿À¸¶Ä¿´Â °£¼¼Æ÷ µ¶¼º°ú Áúº´ ÁøÇà°ú °ü·ÃµÈ ´Ù¸¥ ¼¼Æ÷ ¹ÝÀÀÀ» °¨ÁöÇÏ¿© °£ °Ç° »óÅ¿¡ ´ëÇÑ Áß¿äÇÑ ÅëÂû·ÂÀ» Á¦°øÇÏ´Â °ÍÀ¸·Î Àνĵǰí ÀÖ½À´Ï´Ù.
ÃÖÁ¾ ¿ëµµÀÇ °üÁ¡¿¡¼ ½ÃÀåÀº Á¦¾à ¹× CRO(ÀǾàǰ °³¹ß ¾÷¹« ¼öŹ ±â°ü) ¾÷°è, º´¿ø, Áø´Ü ½ÇÇè½Ç, Çмú ¿¬±¸ ±â°üÀ¸·Î ³ª´ ¼ö ÀÖ½À´Ï´Ù. Á¦¾à ¹× CRO ¾÷°è´Â 2024³â¿¡´Â Àüü ¸ÅÃâÀÇ 42.2%¸¦ âÃâÇØ ÁÖµµÀûÀÎ ÁöÀ§¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÌÁ¡Àº ¾÷°è°¡ ½Å¾à, ÀÓ»ó½ÃÇèÀÇ Ãþº°È, Ä¡·á ¸ð´ÏÅ͸µÀ» À§ÇÑ È¿°úÀûÀÎ ¹ÙÀÌ¿À¸¶Ä¿¿¡ °ÇÏ°Ô ÀÇÁ¸ÇÑ´Ù´Â °ÍÀ» ¹Ý¿µÇÕ´Ï´Ù. ÀǾàǰ °³¹ß±â¾÷ÀÌ Ä¡·áÁ¦ Èĺ¸ÀÇ °³¹ß±â°£ ´ÜÃà°ú Á¤¹Ðµµ Çâ»óÀ» ¸ñÇ¥·Î ÇÏ´Â °¡¿îµ¥, ¹ÙÀÌ¿À¸¶Ä¿´Â °³¹ß »çÀÌŬ Àü¹Ý¿¡ °ÉÃÄ À¯È¿¼º°ú ¾ÈÀü¼ºÀ» Æò°¡Çϴµ¥ ÀÖ¾î¼ ÇʼöÀûÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÇÑÆí CRO´Â ¹ÙÀÌ¿À¸¶Ä¿ÀÇ °ËÁõ ¹× ½ÃÇèÀ» À§ÇÑ ±â¼úÀû, ±ÔÁ¦Àû Àü¹®Áö½ÄÀ» Á¦°øÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ³ë·ÂÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. CROÀÇ Âü¿©´Â ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ¹ß°ß¿¡¼ ÀÓ»óÀû ÀÀ¿ëÀ¸·ÎÀÇ ÀüȯÀ» È¿À²ÈÇϰí Ç¥Àû Ä¡·áÀÇ °³¹ßÀ» °ÈÇÏ°í ½ÃÀåÀÇ ±Þ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
Áö¿ªÀûÀ¸·Î ¹Ì±¹Àº NASH ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¾ßÀÇ ÁÖ¿ä ¼ºÀå ¿£ÁøÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ½ÃÀ常À¸·Îµµ 2024³â¿¡´Â 3¾ï880¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2034³â¿¡´Â ¾à 29¾ï ´Þ·¯·Î ±ÞÁõÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. °£ ÁúȯÀÇ ºÎ´ãÀÌ Áõ°¡Çϰí ÀÖ´Â °Í, °íµµÀÇ Áø´Ü ±â¼úÀ» ¼Æ÷Æ®ÇÒ ¼ö ÀÖ´Â °ß°íÇÑ Çコ Äɾî ÀÎÇÁ¶ó°¡ Á¤ºñµÇ°í ÀÖ´Â °Í µî, ¸î°³ÀÇ ¿äÀÎÀÌ ÀÌ Å« ±ËµµÀÇ ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ³ëÀÎÀº ¸¸¼º °£ ÁúȯÀÇ À§ÇèÀÌ ³ô°í Àû½Ã¿¡ Áø´Ü °³ÀÔÀÌ ÇÊ¿äÇϱ⠶§¹®ÀÔ´Ï´Ù. ºñħ½ÀÀûÀÎ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ÁÖ¸ñ°ú ÇÔ²², °Ç° °ü¸®¿¡¼ Áø´Ü¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖ´Â °Íµµ ¹ÙÀÌ¿À¸¶Ä¿ ±â¼ú ¼ö¿ä¸¦ ´õ¿í ²ø¾î¿Ã¸®°í ÀÖ½À´Ï´Ù. Á¤È®Çϰí Á¶±â ¹ß°ß µµ±¸¿¡ ´ëÇÑ ¿ä±¸´Â Àü·Ê ¾øÀÌ ³ô¾ÆÁö°í ÀÖÀ¸¸ç, ¹Ì±¹Àº ±Þ¼ÓÇÑ ±â¼ú Áøº¸¿Í Â÷¼¼´ë °Ë»ç ÇÁ·ÎÅäÄÝÀÇ ÅëÇÕÀ¸·Î ÀÌ ¼ö¿ä¿¡ ºÎÀÀÇÏ´Â ÃÖÀü¼±¿¡ ÀÖ½À´Ï´Ù.
NASH ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå °æÀï ±¸µµ´Â ¿©ÀüÈ÷ ÇÕ¸®ÀûÀ¸·Î ´ÜÆíȵǰí ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ß¸¦ ÀüÁø½Ã۰í ÀÖ½À´Ï´Ù. ´ÙÁßÈ Ç÷§Æû°ú AI ÅëÇÕ ºÐ¼® µîÀÇ Çõ½ÅÀº ÀÓ»ó°ú ¿¬±¸ÀÇ µÎ Àå¸é¿¡¼ ¹ÙÀÌ¿À¸¶Ä¿ µ¥ÀÌÅ͸¦ ¼öÁý, ÇØ¼®, Àû¿ëÇÏ´Â ¹æ¹ýÀ» º¯È½Ã۰í ÀÖ½À´Ï´Ù.
The Global Non-alcoholic Steatohepatitis Biomarkers Market was valued at USD 1.5 billion in 2024 and is estimated to grow at a CAGR of 25.8% to reach USD 14.8 billion by 2034. NASH biomarkers are biological indicators that help evaluate the presence and progression of NASH, a severe liver condition that evolves from non-alcoholic fatty liver disease (NAFLD). As healthcare providers increasingly prioritize early detection and targeted interventions, the demand for such biomarkers has grown considerably. The push for proactive liver disease screening is further reinforced by evolving clinical recommendations targeting at-risk populations. This includes individuals with metabolic disorders such as obesity and type 2 diabetes, who are more likely to develop NASH.
As awareness of liver-related complications continues, healthcare systems are integrating biomarker-based diagnostic strategies to improve patient outcomes. These tools offer the potential to monitor disease progression, assess treatment efficacy, and identify patients most likely to benefit from emerging therapies. Their growing role in personalized medicine drives a significant shift in how liver diseases are diagnosed and managed. Increasing preference for minimally invasive methods and growing adoption of precision diagnostics in clinical research have further cemented the importance of NASH biomarkers in modern healthcare.
Market Scope | |
---|---|
Start Year | 2024 |
Forecast Year | 2025-2034 |
Start Value | $1.5 Billion |
Forecast Value | $14.8 Billion |
CAGR | 25.8% |
The market is segmented by biomarker type into oxidative stress biomarkers, hepatic fibrosis biomarkers, serum biomarkers, apoptosis biomarkers, and others. Among these, serum biomarkers accounted for the largest share of revenue, contributing 32.8% in 2024. This segment's dominance is primarily due to the convenience of blood sampling, non-invasive procedures, and their frequent use in diagnosis, monitoring, and prognosis. Serum-based biomarkers are recognized for offering vital insights into liver health by detecting hepatocyte injury and other cellular responses linked to disease progression. Their application across both clinical settings and research environments adds to their widespread utility and market traction.
In terms of end use, the market is divided into the pharmaceutical and contract research organization (CRO) industry, hospitals, diagnostic laboratories, and academic research institutes. The pharmaceutical and CRO industry held the leading position in 2024, generating 42.2% of the overall revenue. This dominance reflects the industry's strong reliance on validated biomarkers for drug discovery, clinical trial stratification, and treatment monitoring. As drug developers seek to accelerate timelines and increase the precision of their therapeutic candidates, biomarkers have become essential in assessing efficacy and safety throughout the development cycle. CROs, on the other hand, support these efforts by offering technical and regulatory expertise for biomarker validation and testing. Their involvement has streamlined the transition from biomarker discovery to clinical application, bolstering the development of targeted treatments and contributing to faster market growth.
Geographically, the United States has emerged as a key growth engine within the NASH biomarkers space. The US market alone was valued at USD 308.8 million in 2024 and is anticipated to surge to approximately USD 2.9 billion by 2034. Several factors contribute to this significant trajectory, including a rising burden of liver-related conditions and a robust healthcare infrastructure capable of supporting advanced diagnostic technologies. The growing aging population is also a major driver, as older individuals face a higher risk of chronic liver diseases and require timely diagnostic interventions. Increasing healthcare investments in diagnostics, coupled with a focus on non-invasive solutions, are further driving demand for biomarker technologies. The need for accurate and early detection tools has never been greater, and the US is at the forefront of meeting this demand with rapid technological advancements and integration of next-generation testing protocols.
The competitive landscape of the NASH biomarkers market remains moderately fragmented. A mix of specialized biomarker firms and diagnostic solution providers is actively shaping the space, with leading players collectively capturing around 40% of the total market share. These companies are advancing the field by incorporating novel technologies and forming partnerships aimed at enhancing precision medicine capabilities. Innovations such as multiplexed platforms and AI-integrated analytics are transforming how biomarker data is collected, interpreted, and applied in both clinical and research settings. As the market continues to evolve, technological upgrades and cross-industry collaborations are expected to accelerate the adoption of more efficient, scalable, and patient-centered biomarker solutions.